With the commercialization of Qvella technology for Positive Blood Culture (PBC) processing, healthcare facilities can now get results up to 24 hours faster than current methods
Immune response confirmed in stand-alone influenza vaccine and combination vaccine with a potential path forward for both
The latest technology from ZEISS empowers surgeons with one complete, digitally integrated cataract workflow for efficiency without compromise
This partnership allows both companies to become first movers to bridge an inevitable gap with the largest organizations in the pharmaceutical, nutraceutical, cosmetic, and veterinary sectors
Through the contract, the company will supply two key GMP intermediates for one of the 'patented drugs' of the innovator pharmaceutical customer
Turn has developed a novel cell rejuvenating platform with significant potential for application in an array of age-related diseases
A comprehensive assessment of the organisational systems for governance, management, operations and consistency in delivered results, this certification is an endorsement of the company's export capabilities and manufacturing prowess
The company plans to file its NDA in China and MAA in the EU in 2022, making Hansizhuang potentially to be the world's first PD-1 inhibitor for the first-line treatment of SCLC
Exclusive distribution agreement brings Point-Of-Care (POC) haematology diagnostics to new regions in the Middle East
BioFluidica LiquidScan harnesses the power of microfluidics
Subscribe To Our Newsletter & Stay Updated
